Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors Kelly K; Swords R; Mahalingam D; Padmanabhan S; Giles FJTarget Oncol 2009[Apr]; 4 (2): 99-105Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.|Benzamides[MESH]|Cell Proliferation/drug effects[MESH]|Cytotoxicity, Immunologic/drug effects/immunology[MESH]|Dasatinib[MESH]|Humans[MESH]|Imatinib Mesylate[MESH]|Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy/immunology/pathology[MESH]|Lymphocyte Activation/drug effects[MESH]|Pericardial Effusion/etiology/prevention & control[MESH]|Piperazines/administration & dosage/adverse effects[MESH]|Pleural Effusion/etiology/prevention & control[MESH]|Protein Kinase Inhibitors/*adverse effects/therapeutic use[MESH]|Protein-Tyrosine Kinases/antagonists & inhibitors[MESH]|Pyrimidines/administration & dosage/*adverse effects[MESH]|Receptor, Platelet-Derived Growth Factor beta/*antagonists & inhibitors[MESH]|Serositis/*chemically induced/complications/diagnosis/immunology[MESH]|Thiazoles/administration & dosage/*adverse effects[MESH]|Treatment Outcome[MESH] |